One way we facilitate translation of technology is by hosting inventors and their startup companies based on Northwestern technology, especially technologies that are developed in the Simpson Querrey Institute (SQI) laboratories.
In addition to providing incubator space in our laboratories and offices when available, equipment and services offered by the SQI core facilities are open to startup companies.
Companies hosted by SQI include Amphix Bio, Dimension Inx, Epicore Biosystems, NeuroLux and Zylem Biosciences.
Amphix Bio develops synthetic nanofibers that are designed with biological signals to direct cell behavior for tissue regeneration. These nanofiber formulations are liquids or soft gels, making them ideal for minimally invasive therapies to promote regeneration in cartilage, muscle, bone, heart, brain and spinal cord tissues.
Dimension InxWith its unique and proprietary 3D-Painting technologies, Dimension Inx provides an extensive range of innovative material products compatible with advanced manufacturing processes, including 3D-printing, as well as final manufactured product and service solutions for a wide variety of medical and non-medical industries.
Epicore BiosystemsEpicore Biosystems has developed low-cost and skin-like wearable microfluidic solutions that are capable of noninvasively measuring sweat biomarkers and physiology, in real time. Founded in 2017 as a spinout company from SQI's Center for Bio-Integrated Electronics, Epicore has partnered with Fortune 100 companies, the Department of Defense and leading research hospitals to drive personalized care with wearable microfluidic products.
NeuroLuxNeuroLux has developed a fully implantable and ultralightweight system to facilitate optogenetic testing and data. Two members of SQI's Center for Bio-Integrated Electronics—director John Rogers and engineering advisor and collaborator Anthony Banks—co-founded this startup with two other collaborators in 2015.
Zylem BiosciencesZylem Biosciences is a startup biotechnology company developing targeted medicines that uniquely mimic features of natural biologics. Zylem’s lead compound (ZYL-001) directly targets pathologic cholesterol metabolism in cancer, inflammation, cardiovascular disease, and other conditions.